secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001213900-22-023969
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q1 revenue up 22% to $13.7M; GAAP net loss widens to $3.8M
---------------------------------------------------------------------

- Revenue $13.7M, +22% YoY; gross margin 59% vs 55%.
- GAAP net loss $3.8M ($0.21 per share) vs loss $0.6M ($0.04) in Q1 2021.
- Non-GAAP net loss $0.1M ($0.01 per share); cash $89.0M.
- Reaffirmed FY2022 revenue guidance $80-85M (31-39% growth) and gross margin 57-60%.
- Completed EvinceMed acquisition, a specialty drug prescription initiation platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022023969/0001213900-22-023969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022023969/ea159377-8k_optimizerx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-023969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer